Foundation model AI converging with computational drug discovery and protein design after a major biotech acquisition
| | |

Anthropic Just Bought a Drug Discovery Startup for $400M. Here Is What It Means for Healthcare AI.

ByThe Healthcare Discovery Team

A foundation model company just paid $400 million in stock for a team of fewer than 10 people. The implications for drug discovery, precision medicine, and the entire healthcare AI…

Healthcare Discovery lipoprotein(a) RNA therapy cardiovascular risk 2026 showing inherited Lp(a) risk and RNA silencing in the liver
| | |

Lipoprotein(a) Is the Inherited Heart Attack Risk 1.4 Billion People Carry: Inside the RNA Therapies Racing to Silence It

ByThe Healthcare Discovery Team

Lipoprotein(a) is a genetically inherited cardiovascular risk factor that affects roughly one in five people worldwide and cannot be meaningfully lowered by statins, diet, or exercise. In 2026, a new…

David Fajgenbaum of Every Cure, the nonprofit focused on AI-powered drug repurposing
| | |

The Cure Hiding in Plain Sight: How Every Cure Is Rewriting the Rules of Drug Discovery

ByThe Healthcare Discovery Team

Every Cure is a nonprofit using AI and drug repurposing to uncover treatments hidden inside existing medicines. Founded by physician-scientist David Fajgenbaum after a repurposed drug saved his own life,…

Dynamic protein ribbons shifting through conformations as AI maps motion for drug discovery
| | |

MIT, ASU, and the New Frontier of Protein Motion: Why Drug Discovery Is Moving Beyond Static Structure

ByThe Healthcare Discovery Team

Two university-led advances point to the next chapter in AI-enabled drug discovery. MIT’s VibeGen designs proteins by their motion profiles. ASU’s fast sampling method accelerates access to conformational landscapes. Together,…